In triple-negative breast cancer (TNBC), higher ADAM9 expression correlates significantly with poorer outcomes, while inhibition of ADAM9 expression lowers TNBC cell aggressiveness by suppressing AKT/NF-κB signaling 38. Here, AKT1 is linked to triple-negative breast carcinoma.